CY1121637T1 - Αντι-dkk-1 αντισωματα - Google Patents

Αντι-dkk-1 αντισωματα

Info

Publication number
CY1121637T1
CY1121637T1 CY20191100531T CY191100531T CY1121637T1 CY 1121637 T1 CY1121637 T1 CY 1121637T1 CY 20191100531 T CY20191100531 T CY 20191100531T CY 191100531 T CY191100531 T CY 191100531T CY 1121637 T1 CY1121637 T1 CY 1121637T1
Authority
CY
Cyprus
Prior art keywords
dkk
antibodies
human
pathogenesis
mediated
Prior art date
Application number
CY20191100531T
Other languages
English (en)
Inventor
Marcio Chedid
Ryan James Darling
Rachelle Jeanette Galvin
Barbara Anne Swanson
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1121637T1 publication Critical patent/CY1121637T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η εφεύρεση παρέχει ανθρώπινα τροποποιημένα αντισώματα, θραύσματα δεσμεύσεως αντιγόνου αυτών, τα οποία συνδέονται με την ανθρώπινη DKK-1, και αναστέλλουν τη λειτουργία αυτής, και τα οποία είναι αποτελεσματικά για την αγωγή νόσων στις οποίες η παθογένεια διαμεσολαβείται από την DKK-1.
CY20191100531T 2009-04-10 2019-05-17 Αντι-dkk-1 αντισωματα CY1121637T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16841109P 2009-04-10 2009-04-10
EP10712681.5A EP2417158B9 (en) 2009-04-10 2010-04-06 Dkk-1 antibodies
PCT/US2010/030039 WO2010117980A1 (en) 2009-04-10 2010-04-06 Dkk-1 antibodies

Publications (1)

Publication Number Publication Date
CY1121637T1 true CY1121637T1 (el) 2020-07-31

Family

ID=42199718

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20171101022T CY1119399T1 (el) 2009-04-10 2017-09-29 Aντι-dkk-1 αντισωματα
CY20191100531T CY1121637T1 (el) 2009-04-10 2019-05-17 Αντι-dkk-1 αντισωματα
CY20211100700T CY1124412T1 (el) 2009-04-10 2021-08-06 Aνti-dkk-1 αντισωματα

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20171101022T CY1119399T1 (el) 2009-04-10 2017-09-29 Aντι-dkk-1 αντισωματα

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20211100700T CY1124412T1 (el) 2009-04-10 2021-08-06 Aνti-dkk-1 αντισωματα

Country Status (30)

Country Link
US (1) US8148498B2 (el)
EP (3) EP3514173B8 (el)
JP (1) JP5759977B2 (el)
KR (3) KR20110124364A (el)
CN (1) CN102388065B (el)
AR (1) AR075989A1 (el)
AU (1) AU2010234611B2 (el)
BR (1) BRPI1014157B1 (el)
CA (1) CA2758252C (el)
CY (3) CY1119399T1 (el)
DK (3) DK2417158T4 (el)
EA (1) EA021401B1 (el)
ES (3) ES2644244T3 (el)
HR (3) HRP20171400T1 (el)
HU (3) HUE034625T2 (el)
IL (1) IL214845A (el)
LT (3) LT3514173T (el)
ME (2) ME02798B (el)
MX (1) MX2011010707A (el)
NZ (1) NZ595011A (el)
PL (3) PL3514173T3 (el)
PT (3) PT2930184T (el)
RS (3) RS56505B1 (el)
SG (1) SG175244A1 (el)
SI (3) SI3514173T1 (el)
TR (1) TR201907261T4 (el)
TW (1) TWI546079B (el)
UA (1) UA103916C2 (el)
WO (1) WO2010117980A1 (el)
ZA (1) ZA201107256B (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010131185A1 (en) 2009-05-12 2010-11-18 Pfizer Inc. Blocking anti-dkk-1 antibodies and their uses
MX363407B (es) 2012-12-10 2019-03-22 Biogen Ma Inc Anticuerpos del antigeno 2 de celulas dendriticas anti-sangre y usos de los mismos.
CA2981115C (en) * 2015-05-18 2022-05-31 Eli Lilly And Company Anti-dkk-1-anti-rankl bispecific antibody compounds
JP7525980B2 (ja) * 2015-08-28 2024-07-31 アレクトル エルエルシー 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法
SG11201803520PA (en) 2015-11-03 2018-05-30 Janssen Biotech Inc Antibodies specifically binding pd-1 and their uses
EP3532099A1 (en) 2016-10-26 2019-09-04 Leap Therapeutics, Inc. Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody
BR112021000427A2 (pt) * 2018-07-11 2021-04-06 Momenta Pharmaceuticals, Inc. Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulado direcionado a ctla-4
CN112121147B (zh) * 2019-06-24 2023-07-04 中国人民解放军海军特色医学中心 多肽在治疗或预防骨髓瘤药物中的应用、多肽、核酸、药物及重组表达载体
MX2022003396A (es) 2019-09-19 2022-04-19 Leap Therapeutics Inc Uso de inhibidores de dkk-1 para tratar el cancer.
US20240141023A1 (en) * 2019-11-22 2024-05-02 Leap Therapeutics, Inc. Methods of treating cancer using dkk-1 inhibitors
KR102494042B1 (ko) * 2020-11-20 2023-02-07 주식회사 하울바이오 인간모유두세포의 성장을 촉진하는 항-dkk-1 항체 및 이의 용도
CN112592402B (zh) * 2020-12-02 2022-04-26 杭州奕安济世生物药业有限公司 抗dkk2抗体、包含该抗dkk2抗体的组合物及其用途
EP4288098A1 (en) * 2021-02-05 2023-12-13 Omeros Corporation Biomarker for assessing the risk of developing acute covid-19 and post-acute covid-19
EP4398889A1 (en) 2021-09-10 2024-07-17 Leap Therapeutics, Inc. Combination therapy
WO2024015463A1 (en) 2022-07-12 2024-01-18 Leap Therapeutics, Inc. Combination therapy
CN116589590B (zh) * 2023-03-21 2024-03-26 浙江大学 一种特异性抗异菌脲的单克隆抗体及其重组表达质粒

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
PT975755E (pt) 1997-04-16 2007-06-26 Millennium Pharm Inc Proteínas crsp (proteínas segregadas ricas em cisteínas), moléculas de ácido nucleico que as codificam e suas utilizações
DE19747418C1 (de) 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US7446181B2 (en) * 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
ES2312205T3 (es) 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
WO2001057190A2 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
CA2443123A1 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
BR0209836A (pt) 2001-05-17 2004-12-07 Genome Therapeutics Corp Método para regular a atividade de lrp5, lrp6 ou hbm em um paciente, e do caminho dkk-wnt em um paciente, para modular a massa óssea e os nìveis de lipìdeo em um paciente, para diagnosticar a massa óssea alta ou baixa e/ou os nìveis de lipìdeos altos ou baixos em um paciente, para triar um composto que modula a interação de dkk com lrp5, lrp6, hbm ou um fragmento de ligação de dkk de lrp5, lrp6 ou hbm, e de dkk com uma proteìna que interage com a dkk, composição, composição farmacêutica, métodos para identificar compostos que modulem as interações da dkk e lrp5/lrp6/hbm, e para identificar parceiros de ligação para uma proteìna de dkk, ácido nucléico que codifica um aptâmero peptìdico da proteìna que interage com dkk, vetor, método para detectar uma atividade moduladora de um composto, animal transgênico, método para identificar compostos potenciais que modulem a atividade da dkk, aptâmero peptìdico, anticorpo ou fragmento de anticorpo, e, métodos para identificar proteìnas que interagem com a dkk modulando a interação da dkk com o caminho de sinalização wnt, para identificar compostos que modulem a interação da dkk com o caminho de sinalização wnt, para testar compostos que modulam a atividade mediada pela dkk em um mamìfero, e para triar compostos ou composições que modulam a interação da dkk e uma proteìna que interage com a dkk
US20040038860A1 (en) * 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
CA2466483A1 (en) 2001-11-07 2003-07-03 John D. Shaughnessy Diagnosis prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling
US7371736B2 (en) * 2001-11-07 2008-05-13 The Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
US7308364B2 (en) * 2001-11-07 2007-12-11 The University Of Arkansas For Medical Sciences Diagnosis of multiple myeloma on gene expression profiling
US7642238B2 (en) * 2002-12-05 2010-01-05 Shaughnessy John D Molecular determinants of myeloma bone disease and uses thereof
US20050084494A1 (en) * 2003-05-21 2005-04-21 Darwin Prockop Inhibitors of Dkk-1
AU2004274861A1 (en) 2003-06-06 2005-03-31 Wyeth Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby
AU2005267722B2 (en) * 2004-08-04 2009-10-08 Amgen Inc. Antibodies to Dkk-1
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
WO2008097510A1 (en) * 2007-02-08 2008-08-14 Merck & Co., Inc. Antibodies specific for dkk-1
BRPI1014535A2 (pt) * 2009-05-07 2016-04-05 Novatis Ag composições e métodos de uso para moléculas de ligação a dickkopf-1 ou dickkopf-4 ou ambas

Also Published As

Publication number Publication date
LT2417158T (lt) 2017-10-10
BRPI1014157A2 (pt) 2020-09-29
CA2758252A1 (en) 2010-10-14
PT2417158T (pt) 2017-10-23
CY1124412T1 (el) 2022-07-22
LT3514173T (lt) 2021-09-10
KR20140033523A (ko) 2014-03-18
HUE043904T2 (hu) 2019-09-30
HUE055376T2 (hu) 2021-11-29
SI2930184T1 (sl) 2019-06-28
MX2011010707A (es) 2012-02-28
DK2417158T4 (da) 2018-01-29
HUE034625T2 (en) 2018-02-28
SI3514173T1 (sl) 2021-09-30
PL2930184T3 (pl) 2019-10-31
SG175244A1 (en) 2011-12-29
RS58612B1 (sr) 2019-05-31
HRP20171400T1 (hr) 2017-11-03
ZA201107256B (en) 2013-03-27
TWI546079B (zh) 2016-08-21
ES2728911T3 (es) 2019-10-29
DK2930184T3 (da) 2019-05-13
ME02798B (me) 2018-01-20
DK2417158T3 (en) 2017-10-16
US8148498B2 (en) 2012-04-03
EP2417158B9 (en) 2017-12-06
EP3514173B1 (en) 2021-06-23
KR101461362B1 (ko) 2014-11-13
EP2930184B1 (en) 2019-03-27
EP2930184A1 (en) 2015-10-14
JP5759977B2 (ja) 2015-08-05
BRPI1014157B1 (pt) 2022-01-18
EP3514173A1 (en) 2019-07-24
WO2010117980A1 (en) 2010-10-14
EA201171237A1 (ru) 2012-04-30
KR20140090273A (ko) 2014-07-16
AU2010234611B2 (en) 2013-02-07
CA2758252C (en) 2015-02-24
JP2012523417A (ja) 2012-10-04
RS56505B1 (sr) 2018-02-28
PT3514173T (pt) 2021-08-16
HRP20190643T1 (hr) 2019-05-31
AU2010234611A1 (en) 2011-10-20
RS62214B1 (sr) 2021-09-30
EP2417158B1 (en) 2017-08-02
IL214845A0 (en) 2011-11-30
UA103916C2 (en) 2013-12-10
PL2417158T3 (pl) 2017-12-29
IL214845A (en) 2016-06-30
LT2930184T (lt) 2019-05-10
TR201907261T4 (tr) 2019-06-21
EP2417158A1 (en) 2012-02-15
EP3514173B8 (en) 2021-08-04
PT2930184T (pt) 2019-06-17
KR20110124364A (ko) 2011-11-16
ES2644244T3 (es) 2017-11-28
TW201100101A (en) 2011-01-01
CN102388065B (zh) 2014-09-03
HRP20211343T1 (hr) 2021-11-26
EA021401B1 (ru) 2015-06-30
DK3514173T3 (da) 2021-08-02
SI2417158T1 (sl) 2017-10-30
US20100260754A1 (en) 2010-10-14
NZ595011A (en) 2013-05-31
CY1119399T1 (el) 2018-02-14
ME03378B (me) 2020-01-20
PL3514173T3 (pl) 2022-01-17
CN102388065A (zh) 2012-03-21
ES2887176T3 (es) 2021-12-22
AR075989A1 (es) 2011-05-11

Similar Documents

Publication Publication Date Title
CY1124412T1 (el) Aνti-dkk-1 αντισωματα
CY1123883T1 (el) Ανθρωποποιημενα αντισωματα κατα της liv-1 και χρηση αυτων για τη θεραπευτικη αντιμετωπιση του καρκινου
CY1116886T1 (el) C-met αντισωματα
CY1120471T1 (el) Αντισωματα κατα του cd70
CY1122107T1 (el) Τροποποιημενες πρωτεϊνες δεσμευσης οι οποιες αναστελλουν την αλληλεπιδραση υποδοχεα vegf-a
CY1126300T1 (el) Bcma (cd269/tnfrsf17) - πρωτεϊνες δεσμευσης
CY1123404T1 (el) Αντι-girt αντισωματα
CY1119994T1 (el) Συνθεσεις και μεθοδοι για αυξηση της μυϊκης μαζας και της μυϊκης δυναμης ανταγωνιζοντας ειδικα ton gdf8 και/ή την ακτιβινη α
CY1119445T1 (el) Αντισωματα εναντι του ανθρωπινου gdf8
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
CY1121097T1 (el) Ανθρωπινα αντισωματα κατα toy gfr 3 και μεθοδοι χρησης αυτων
CY1117563T1 (el) Αντισωματα κατα her3 και χρησεις αυτων
CY1121368T1 (el) Αντισωματα anti-asic1 και χρησεις αυτων
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1121538T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi)
CO6680687A2 (es) Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas
CY1122978T1 (el) Αντισωματα εναντι-vla-4
CY1116842T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
CY1114872T1 (el) Συνθεσεις και μεθοδοι χρησης αντισωματων εναντι της σκληροστεϊνης
CY1121167T1 (el) Βελτιωμενα αντισωματα εναντι της ανθρωπινης φρακταλκινης και χρησεις αυτων
CY1114271T1 (el) Αντισωματα εξουδετερωσης, ανθρωπινου κυτταρομεγαλοϊου και χρηση αυτων
ECSP12011885A (es) Inmunoglobulinas con dominio variable dual
CY1118244T1 (el) Αντισωματα κατα της il-25
EA202091315A3 (ru) Антитела человека, связывающиеся с g-белком rsv